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Background: High-intensity focused ultrasound (HIFU) allows to inflict intracorporal thermal lesions without
penetrating the skin or damaging the surrounding tissue. This analysis intends to assess the magnitude of
HIFU-induced ablations within benign thyroid nodules using scintigraphic imaging with 99mTc.
Methods: Ten cold, hot, or indifferent nodules were treated using multiple pulses of HIFU to induce temperatures
of around 85°C within the ablation zone. Pre- and posttreatment, uptake values of 99mTc-pertechnetate
or 99mTc-MIBI were recorded. The pre-post reduction of nodular uptake was evaluated to assess ablation
magnitude.
Results: Relative nodular uptake in relation to total thyroidal uptake decreased after one session of HIFU in all cases.
Median 99mTc-MIBI uptake reduction was 35.5% (ranging from 11% to 57%; p < 0.1), while 99mTc-pertechnetate
scintigraphy showed a median uptake reduction of 27% (range 10% to 44%; p < 0.1). No major complications were
observed.
Conclusions: HIFU appears to be safe and is an easy to perform means of thermal ablation. This study shows that
HIFU treatment in thyroidal nodules can be evaluated by scintigraphic means shortly after the intervention. Due to
small sample size, the exact magnitude of HIFU ablation efficiency in thyroidal nodules remains a value to be
assessed in a larger study.
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Thyroid surgeries are among the most common ones in
western countries; the prevalence of thyroidal nodules
(TNs) in the general population of a developed society
is rather high (found in 4%–8% with the use of
palpation, in 19%–67% using ultrasound (US) [1], in
Germany, 21.9% of the working population have un-
detected TNs [2]). Especially for the treatment of benign
TNs, risks [3] and costs of surgery seem rather high.
Many patients that face only cosmetic or swallowing
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for many years were given only the alternative of radio-
isotope therapy (RIT) in case of hot nodules. Over the
last decades, different approaches have been developed,
favoring not a removal, but only the local elimination of
the abnormal tissue. Recent studies indicate that min-
imally invasive thermal ablation using microwave [4,5]
or radio frequency [6-8] might provide an efficient
method for achieving this goal. Yet, they maintain, just
like local ablation via ethanol injection [9,10], an
invasive characteristic; a disadvantage, ablation by high-
intensity focused ultrasound (HIFU), does not necessar-
ily share. HIFU is in use for several years for the treat-
ment of prostate cancer [11], uterine fibroids [12], andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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opment for liver and kidney tumors [14]. So far, the ap-
plication of HIFU on the thyroid is only reported
concerning a preliminary experimental animal study
[15,16], and one single case study on a human TN [17].
The feasibility of the method for treatment of majorly
solid nodules has been shown in a study in which hu-
man thyroids were treated with HIFU 2 weeks before
the scheduled thyroidectomy and then assessed histo-
logically [18].
Thermal ablation utilizes the necrotizing effects on liv-
ing human tissue of temperatures between 60°C and
100°C, as vaporization and carbonation effects start to
occur above 100°C only [19]. The ablated tissue presents
itself as a coagulation necrosis that over time will be dis-
integrated by immunology cells, resulting in lasting
shrinkage of the nodule.
Like radio frequency or microwave ablation, HIFU
treatment is conducted under US guidance. As with
ultrasonography, the targeted tissue's functional destruc-
tion is neither confirmable nor quantifiable at a suffi-
cient level; treatment success cannot be evaluated during
the procedure and thus requires a postinterventional in-
vestigation. Scintigraphic imaging has been shown to be
a promising means for the purpose of analyzing micro-
wave ablated TNs [4]. This analysis intents to verify
whether this is true for HIFU ablation as well, and if so,
assess HIFU ablation magnitude using scintigraphic
imaging.
Methods
This analysis was an open label study. Patients over 18
years of age with at least one thyroid nodule with no
signs of malignancy who met the protocol's eligibility
criteria were recruited.
Inclusion criteria
Benign TNs that require treatment for associated prob-
lems like thyrotoxicosis, neck pain, throat hoarseness,
swallowing disorders, discomfort, and/or because of cos-
metic concern. Patient either refuses surgical or RIT or
shows major contraindications to these both treatments.
Exclusion criteria
The exclusion criteria are the presence of a malignant
nodule (diagnosed by an atypical finding in cold nodules
in preliminary 99mTc-MIBI scintigraphy confirmed by
histological indication of follicular proliferation based on
fine needle aspiration biopsy (FNAB)) or critical close-
ness of the nodule to sensible structures such as recur-
rent nerve, trachea, esophagus, or carotid artery.
Generally, HIFU treatment was presented as an alter-
native to microwave ablation. All ten patients (two
males, eight females, age ranging from 36 to 80 years(median 55 years), each with one target benign TN (six
cold ones, four hot or indifferent)) were included.
Written informed consent was obtained from all ten pa-
tients. They were informed of the known possible adverse
effects of HIFU ablation (skin burn, pain, vocal cord palsy,
tracheal and esophageal injuries, recurrence of the treated
nodule). Written informed consent was also obtained con-
cerning all diagnostic actions. The study was approved by
the ethics commission of the University hospital Frankfurt.
Evaluation
At baseline, all nodules were examined by US to deter-
mine their volume, precise location, echogenicity,
blood perfusion (using US Doppler) and elasticity
(using US elastography). According to the US Doppler,
all nodes were graded either type 1 if no nodular blood
flow was detectable, type 2 if it was minimal, and type 3
if significant blood flow was marked. They were fur-
thermore classified to be of echogenicity type 1 if
hypoechogenic, type 2 if isoechogenic, and type 3 if
hyperechogenic. They were graded ES 1 (blue) if soft,
ES 2 (blue-yellow) if more soft than solid, ES 3 (yellow-
red) if more solid than soft, and ES 4 if predominantly
solid (red) [20].
Additionally, 99mTc scintigraphy was performed to
provide information about nodular functional activity.
Scintigraphic imaging was performed using 75 MBq 99mTc-
pertechnetate 20 min postadministration with a scintillation
camera (Mediso Nucline® TH/22; Mediso, Budapest,
Hungary; acquisition time, 300 s; matrix, 128 × 128 × 16,
low-energy collimator).
Regarding cold nodule imaging, further investigations
to exclude malignancy were conducted in all cases. This
was achieved by additional FNAB cytology of the tissue
in question with subsequent histological examination as
well as a secondary scintigraphic imaging using 99mTc-
MIBI. Generally, the follow-up of cold nodules was also
done with 99mTc-MIBI scintigraphy (441 MBq) using the
same scintillation camera as the pertechnetate scintig-
raphy, only with prolonged acquisition time (500 s) and
different matrix (256 × 256 × 16). All scintigraphic im-
aging was done in compliance to DGN guideline. Postin-
tervention, the nodules were also examined using US, US
Doppler, and US elastography.
Equipment
The HIFU device used for treatment in this study was
the EchoPulse® (Theraclion SA, Malakoff, France), cap-
able of US-guided extracorporeal HIFU treatment with
contemporaneous cooling of the treated area. Its center-
piece is the probe, emitting both the treatment HIFU (3
MHz, piezo-electrically generating 125 W of maximal
sound power) as well as the imaging US (7.5–12 MHz),
that is placed in the midst of the former one, so that the
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the US image. Both acoustic waves pass through a layer
of cooling liquid held by a plastic balloon. The circulat-
ing liquid (10°C) is cooling the adjacent skin above the
treatment area and thus prevents it from any damage
due to heating from energy lost by the treatment echo
on its way to the focal point and heat conducted from
there. One of the many built-in safety provisions is a
laser-based distance measurement between the robotic
arm (holding the probe) and some reference point on
the patient's skin. During treatment, distance changes of
above 1 mm automatically lead to instant pausing of
pulse emission to avoid inaccurate lesion placement due
to patient movement. After such an interruption, repo-
sitioning of patient and/or probe is required before
treatment can continue.
Method and technique
The treatment itself is planned in about 10 to 20 sagittal
and transversal section plane US images by target area
as well as sensible structures (trachea, carotid, skin) be-
ing defined in each of them by the performing physician.
The device creates security margins of 2 mm to the ca-
rotid, 5 mm to the skin, and at least 3 mm to the tra-
chea, which cannot be infringed even when overlapping
with the designated target area.
The focal point itself has the approximate form of a rice
corn of 2 mm diameter and 9 mm length; the ablation
area is a field of many such ellipsoid voxels “standing” side
by side (Additional file 1). During treatment, each such
voxel receives one echo pulse of 4-s duration followed by
a cooling period of 20–40 s, during which the robotic arm
repositions the probe to focus the next site. The usage of
pulsed treatment also helps to prevent the formation of
prefocal cavitations, which could lead to unwanted lesions
in non-focal areas [21]. By default, all voxels that overlap
with the target area and do not infringe any security mar-
gins are treated, but can be deselected manually.
One principle during HIFU treatment for this study
was to maximize ablation zone volume within the tar-
geted nodes. Accordingly, depth placement of the voxels
was chosen to run through the nodule center, and pro-
posed treatment sites were only excluded from execu-
tion if overlapping with the target area was marginal.
Prior to the main ablation procedure, some test pulses
were emitted to the nodule to adjust the echo intensity
to just below the point where the so called heat bubbles
[22] (visible in US and indicating sufficient heating to
induce necrosis in thyroid tissue) emerge. Energy deliv-
ery per site ranged from 87.6 to 192.8 J. The duration of
the procedure was 68 min on average and very
dependent on the number of sites treated as well as fre-
quency of significant patient movement and following
repositioning.Dependent on patient pain toleration levels, treatment
was performed either under local anesthesia with Mecain
or no anesthesia at all.
One day after the intervention, functional imaging
was repeated with 99mTc-pertechnetate for hot and
indifferent and with 99mTc-MIBI for cold nodules to
assess treatment success. As the total uptake of 99mTc-
MIBI or 99mTc-pertechnetate in a specific area of the
thyroid depends on many factors of current individual
metabolism, nodular uptake is only evaluated as the
background is adjusted and in relation to total thyroidal
uptake.Statistics
Statistical analysis was done with the free R statistical
software (developed by the R Development Core Team).
As normal distribution could not be assumed, the tests
for significant changes of uptake reduction, echogenicity,
perfusion, or elasticity of the nodules were performed
with non-parametric methods (Wilcoxon signed rank
test). Significance is defined as p < 0.1.
Due to small sample size and unknown underlying dis-
tributions, correlations are reported using Kendalls τ
and tested against the null hypothesis of τ = 0.Results
Compared to the baseline, median nodular 99mTc-MIBI
uptake reduction was 35.5% (p = 0.016; ranging from
11% to 57%; see Figures 1 and 2), while 99mTc-pertech-
netate scintigraphy showed a median uptake reduction
of 27% (p = 0.063; range 10% to 44%; see Figures 1, 3, 4)
after the intervention.
The US Doppler detected a decrease in nodular perfu-
sion by one class in four cases (p = 0.036). Echogenicity
decreased by one level in five cases (p = 0.019). Among
them, three showed also a decrease in blood perfusion
according to the US Doppler. An increased postablative
nodular solidity by one ES score point was noticed in
five cases (p = 0.019). Three of those showed no change
in neither the US Doppler nor in the echogenicity score.
(For exemplary pre-post images of US, US Doppler, and
US-Elasticity, see Figures 5, 6, 7) respectively.)
The average treatment depth (distance from the skin
to focal point) was 13.6 to 24.5 mm (median 19.85
mm). The total energy delivery (sum of all treatment
pulses energy per patient) ranged from 5.65 to 12.46 kJ
(median 8.4 kJ). The delivered energy per site (pulse
energy each treatment voxel of a patient received)
ranged from 87.6 to 192.8 J (median 157.9 J). The
correlation between energy per site and either 99mTc-
MIBI uptake reduction or 99mTc-pertechnetate uptake
reduction was 0.46 (p = 0.28) and 0.33 (p = 0.75),
respectively.
Figure 1 Relative nodular uptake reduction in percent of preablative nodular uptake.
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7.67 cm3 (median 3.185 cm3). τ correlations between
nodular volume and 99mTc-MIBI or 99mTc-pertechnetate
uptake reduction were −0.66 (p = 0.34) and −0.8 (p =
0.34), respectively.Figure 2 99mTc-MIBI uptake reduction (*significant at p = 0.016).Reported pain levels as well as treatment interruption
frequency due to patient movement seemed to be inde-
pendent of the dose of anesthetic or sedation given to
the patient. Correlation between treatment duration and
treated volume was 0 (p = 1).
Figure 3 99mTc-pertechnetate uptake reduction (*significant at p = 0.063).
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The acceptance of thermal ablation of TNs as a viable
alternative to surgery has increased during the last few
years [23,24].
HIFU is in use for several applications (prostate,
breast [25], uterus) and in testing for some others (tu-
mors of liver [26] and kidney, primary [27] andFigure 4 Exemplary scintigraphical image. Exemplary scintigraphic imag
99mTc-pertechnetate uptake reduction as well as non-nodular uptake recov
clearly visible.secondary hyperparathyroidism [28], late-stage pancre-
atic tumors [29]).
This is the first study using HIFU to treat multiple
patients with thyroidal nodes without a purely aca-
demic motivation (not just before thyroidectomy [18]),
but trying to achieve a significant therapeutic benefit
for the participating patients.ing of a hot nodule (A) pre- and (B) 1 day post-HIFU ablation. Nodular
ery due to ceased suppression by the focal autonomy (circle) is
Figure 5 Plain US image of exemplary thyroidal nodule pre- (A) and 1 day postintervention (B).
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the acquisition of functional information on a molecular
level, with tracers being processed like their physiological
metabolite counterparts. 99mTc-pertechnetate is an iodine
mimicry, and thyroidal uptake is correlating to hormone
production activity. Nodules qualifying themselves as
“hot” in 99mTc-pertechnetate scintigraphy by an increased
uptake of the radioisotope were viewed as benign, since
malignancy of a hot nodule is very unlikely [30].
99mTc-MIBI uptake levels depend mainly on mito-
chondrial activity and cellular membrane potentials;
mitochondrial uptake is described to be significantly in-
creased in malignant thyroid tissue [31].99mTc-MIBI scintigraphy is a method capable of exclud-
ing malignancy of hypofunctional TNs with high accuracy
[32], of up to 92.2% [33]. Preinterventional rule out of
malignancy on cold nodules was done by both 99mTc-
MIBI scintigraphy and FNAB, as the sufficiency for that
task of 99mTc-MIBI scintigraphy alone is still academic-
ally discussed [33]. The negative prediction value of com-
bined 99mTc-MIBI scintigraphy and FNAB is 96.3% [34].
Previous studies have shown that HIFU is capable of
efficiently inducing cell death in the living pig muscle
tissue, leading to non-perfusion and edema formation
confirmed by MRI and the presence of histologically af-
firmed homogeneous necrosis in the targeted area [35].
Figure 6 Doppler US image of exemplary thyroidal nodule pre- (A) and 1 day postintervention (B).
Figure 7 Echogenicity US image of exemplary thyroidal nodule pre- (A) and 1 day postintervention (B).
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HIFU on the thyroid tissue has been reported both for
ewe [15] and human [18] thyroid tissue. Therefore, the
aim of this study was not to prove the destructive ef-
fects of HIFU on thyroid tissue in general but to evalu-
ate how efficiently those effects in the non-surgical
treatment of TNs can be detected and qualified using
scintigraphy.
Postablative treatment assessment using Doppler, elas-
tography, or plain US is fast, easy to perform, and rela-
tively cheap. Yet, especially with the need to grade visual
output, these methods are not very sensitive (none of
them could detect any change in grade in more than
50% of the cases), and quantification of ablation magni-
tude remains vague. The inability of color-coded duplex
sonography (Doppler) to reliably detect cold, hot, or in-
different TNs has been shown before [36]. Nodular per-
fusion decrease due to the ablation does not sufficiently
change the nodular Doppler image to reasonably assess
the treatment.
Assessment by elastography and plain US relies on
changes in the nodules' physical characteristics that may
or may not occur. Findings indicate that HIFU ablation
can induce increased solidity and decreased echogeni-
city, but does not do so in an intensity that reliably
changes corresponding scores.
The uptake of 99mTc-MIBI as well as 99mTc-pertechne-
tate on the other hand is dependent on the physiological
functionality of the tissue in question and thus displays
the attribute the conducting physician really is interested
in, making functional imaging a better tool for ablation
assessment. Treatment success can be measured in
terms of relative nodular uptake reduction; ablation
localization is visualized. Downsides of this method are
higher costs and the patient's exposion to radiation.
Additionally, the dependency between treatment cover-
age (how much of the nodular volume has been treated)
and nodular uptake reduction is not a linear one, as thy-
roidal scintigraphy is a planar imagery, and thus, marker
uptake of tissue ventral and dorsal of the nodular vol-
ume still is detected and accounted for as lying in the
“region of interest”.
Operational shortcomings of the EchoPulse® device
were the long treatment duration of 68 min on average
(range of 42 to 96 min), mainly accredited to long cool-
ing intervals and frequent readjustment pauses due to
patient movement (correlation between treated volume
and thus treated sites count and treatment duration was
0), as well as low imaging quality of the US system used
for planning and controlling the procedure.
Technical constraints leading to the inability to treat
the entirety of each nodule were the generously allocated
security margins around sensible structures, the limita-
tion to only one layer of treatment sites and only onedirection of site alignment, as well as treatment depth
confinement to approximately 3.5 cm.
Due to increased amounts of energy lost before reach-
ing the focal point, target areas lying deeper within the
body generally pose a problem of HIFU also described
for other applications [29].
Despite of low significance, findings indicate that treat-
ment success measured in relative nodular uptake reduc-
tion might be lower in larger nodules (correlation −0.66
to −0.8), most likely due to more nodular tissue lying
ventral and dorsal of the treatment layer. Yet, this effect
might be smaller than expected as with a theoretical
intrafocal 85°C, especially not only pre- but also postfo-
cal temperatures of above 60°C (injuring thyroidal tissue
beyond repair [4]), seem likely. Such off focus lesions
could also explain increased 99mTc-MIBI and 99mTc-per-
technetate uptake reductions at higher levels of energy
delivery per site (correlation 0.33 to 0.46).
A recent study indicates that more degrees of probe ro-
tation freedom may antagonize general main shortcom-
ings of HIFU such as skin burn, long treatment time, and
incomplete ablation [37].
In theory, the treatment of thyroidal nodes with HIFU
could be undergone under general anesthesia in order to
minimize pausing and slight targeting inaccuracies due
to patient movement, but one major advantage of the
method, its outpatient characteristic, would be lost.
Multiple treatments using HIFU on benign TNs might
increase its effectiveness; as months after an ablation,
nodular shrinkage might make parts of it accessible to
HIFU treatment that were unreachable in previous
sessions.
No major complications were observed. Subjective
pain levels during pulse emission were moderate, but
almost neglectable directly after treatment in most
cases. One day postintervention, some patients devel-
oped slight erythrodermia and swelling in the treated
region, presumably due to the consistent cooling dur-
ing the ablation as well as a localized immunological
reaction to the ablated tissue. Also, other authors have
described HIFU to be a treatment method low on com-
plications [38].
Conclusion
HIFU treatment on benign TNs appears to be safe and is
easy to perform. Scintigraphic imaging is a sensible means
for postablative treatment assessment superior to US,
Doppler, and US echogenicity. Therapeutic effectiveness
of HIFU ablation on TNs is decent but could be enhanced
further by increasing possible treatment coverage. Oper-
ational feasibility could be improved by decreasing treat-
ment duration.
Due to small sample size, the findings of this study
need to be verified by larger studies. Also long-term
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ments on benign TNs should be investigated further.
Additional file
Additional file 1: Treatment site alignment model. Visualization
model of treatment site (voxels shown in red) alignment in a TN (blue).
Treatment volume (sum of all voxels) is not congruent with nodular
volume.
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